Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

While the Windows maker did not attribute the activity to a specific threat actor, the use of VS Code tasks and Vercel ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer. The oral drug ...

The stock price of BridgeBio plunged 15% Thursday as Pfizer’s reported decision to withdraw a tafamidis patent in the European Union triggered fears of earlier generic entry in the blockbuster ...

Bing rewrote its webmaster guidelines to cover Copilot grounding, meta directive controls for AI answers, and a softened stance on AI-generated content.

Vutrisiran reduced mortality and cardiovascular events in ATTR-CM patients across all age groups, including those aged 80 and older. The HELIOS-B trial demonstrated consistent benefits in reducing all ...

Featured topics and Editors' Picks from all of ACC's JACC Journals. Vutrisiran and All-Cause Mortality, Prognostic Implication of sTTR Levels in ATTR-CM Studies exploring the association between ...

Recognizing a need to update the 2021 criteria for monitoring disease progression in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a group of international experts shared new proposed ...

SCOTTSDALE, Ariz. (AP) — Los Angeles Dodgers right-hander Roki Sasaki was hit hard and had a tough time finding the strike ...

A new variation of the fake recruiter campaign from North Korean threat actors is targeting JavaScript and Python developers ...

Ahead of the midterm elections, a wave of House and Senate members are retiring or running for other offices.

Attruby (acoramidis) is a prescription drug that’s used to treat transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). Attruby comes as an oral tablet. Attruby contains the active ingredient ...